Drug-eluting stents are more effective than bare-metal stents for off-label uses, and they don't present significant safety issues, a new study finds. The University of Pittsburgh study, published in the New England Journal of Medicine, looked at patients who received stents in tricky areas such as where arteries branch or in grafts from previous surgeries. (Drug-eluting stents are only approved for use in short and straight artery segments.) While restenosis (re-narrowing of the artery) occurred more often in off-label uses than on-label ones, it occurred less often with drug-eluting stents than bare-metal ones. There was no difference in death rates. Another study in the same NEJM issue found almost no difference in survival rate between patients who received stents and those who had bypass surgery. However, bypass had better overall results for patients with multiple lesions.